Idiopathic Gastroparesis Drugs Market Growth & Trends [2030]
Idiopathic Gastroparesis Drugs Market Growth & Trends [2030]
Segments - Global Idiopathic Gastroparesis Drugs Market By Drug (Antiemetic drugs, Prokinetic drugs, Others), By Route of Administration (Oral, Intravenous, Nasal, Transdermal), By Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies), and Region (North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2022-2030
Upcoming
| Report ID :HC-5065
| 4.3 Rating
| 66 Reviews
| 213 Pages
| Format :
Report Description
Idiopathic Gastroparesis Drugs Market Outlook
The global idiopathic gastroparesis market was estimated at USD 1,192.7 Million in 2021 and is anticipated to reach USD 1,699.3 Million by 2030, expanding at a CAGR of 4.1% during the forecast period.
Gastroparesis is a chronic disorder of the stomach that affects the normal and spontaneous movement of the stomach and slows or stops the movement of food from stomach to small intestine. Idiopathic gastroparesis is one of the types of gastroparesis caused by unknown factors.
Gastroparesis occurs on account of damage to the vagus nerve due to injury or illness. It influences the unconstrained development of the stomach muscles. Gastroparesis interferes with normal digestion and causes nausea, vomiting, and abdominal pain.
Antiemetic and prokinetic drugs are commonly used drugs. Medications such as metoclopramide, domperidone, erythromycin, and others are used to treat the condition of idiopathic gastroparesis.
Macro-economic Factors
Government Regulations
Government regulations play an integral role in the approval and branding of gastroparesis drugs for the consumption and treatment of patients. Metoclopramide, a dopamine-2 receptor antagonist, is approved by the US Food and Drug Administration (FDA) for the treatment of gastroparesis. Presently, prucalopride is approved in some countries of Western Europe and in Canada for the management of chronic constipation, and it has the potential to treat symptoms of gastroparesis and delayed gastric emptying.
R&D Activities
Antiemetic and prokinetic drugs are emerging as a significant class of therapeutic agents for the treatment of idiopathic gastroparesis. The treatments available for the diseases are the outcome of previous R&D activities in the field of gastroparesis.
These R&D activities include various steps and perspectives consisting of participants, development phases, citations of related patents, and therapeutic indications with potentially valuable insights for pharmaceutical investors, researchers, and policymakers. R&D activities are a major factor affecting the overall gastroparesis market, the reasons for idiopathic gastroparesis are unknown.
Idiopathic Gastroparesis Drugs Market Dynamics
Market Driver - Increasing Prevalence of Gastroparesis Cases
Cases of gastroparesis are rising day by day. In majority of the cases, diabetes and post-surgical complications are the common origins for this disease. Presently, the cases of idiopathic gastroparesis are increasing, with the unavailability of patient history regarding diabetes or any post-surgical issues. Hence, doctors are prescribing antiemetic and prokinetic drugs for treating patients dealing with constipated state of stomach, abdominal pain, vomiting, and nausea. This factor is driving the market.
Market Driver - Rising approval of medications with different routes of administration
Idiopathic gastroparesis drugs are injected through various routes of administration, as these medications are available in various forms, such as tablets, injections, patches, and nasal medication. Oral tablets are a common form of medication for treating idiopathic gastroparesis. Availability of different forms of the drugs make it convenient for patients to receive the treatment, as the intravenous route of administration is extremely painful. This factor is projected to propel the market.
Market Restraint - Lack of awareness in underdeveloped countries
Idiopathic gastroparesis drugs are popular in developed countries as a treatment method for gastroparesis caused by unknown factors. These drugs are not adopted in underdeveloped countries, due to lack of awareness, low disposable income of people, and lack of knowledge of gastroenterology conditions.
A major part of the global population resides in countries such as China and India; however, the primary consumption of idiopathic gastroparesis is in North America and Europe. Lack of awareness regarding these drugs is expected to affect the growth of the idiopathic gastroparesis drugs market.
Market Opportunity- Increasing Focus on R&D activities by manufacturers
Various companies and research institutes are investing in research and development of gastroparesis drugs. This is expected to create lucrative opportunities for the market players. Increasing number of pipeline products and development of novel treatments are anticipated to create immense opportunities for the market growth during the forecast period. Various articles estimate the current prevalence of gastroparesis at 4% of the US population and rising diagnosis of idiopathic gastroparesis.
Scope of Idiopathic Gastroparesis Drugs Market Report
The report on the global idiopathic gastroparesis drugs market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
|
Attributes |
Details |
|
Report Title |
Idiopathic Gastroparesis Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2021 |
|
Historic Data |
2015 and 2020 |
|
Forecast Period |
2022–2030 |
|
Segmentation |
Drug (Antiemetic drugs, Prokinetic drugs, Other), Route of Administration (Oral, Intravenous, Nasal, Transdermal), Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and the Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered |
EVOKE PHARMA, Cadila Pharmaceuticals, Janssen-Cilag Pty Limited, Abbott, ADVANZ PHARMA, iNova Pharmaceuticals, ANI Pharmaceuticals, Inc., AstraZeneca, Intas Pharmaceuticals Ltd., and Cipla Inc. |
Idiopathic Gastroparesis Drugs Market Segmental Outlook
Based on drugs , the idiopathic gastroparesis drugs market is segmented into antiemetic drugs, prokinetic drugs, and others. The antiemetic drugs segment accounted for a significant market share during the forecast period. These drugs include metoclopramide, Zofran, prochlorperazine, and promethazine.
These drugs are used to treat gastrointestinal symptoms such as constipation, bloating, abdominal discomfort, and vomiting. It works by increasing the movements or contractions of the stomach and intestines. Easy availability, efficacy, high usage, and medication applicability in treating gastroparesis are major factors that are projected to boost the segment during the forecast period.
On the basis of route of administration, the idiopathic gastroparesis drugs market is segregated into oral, intravenous, nasal, and transdermal. The oral segment is expected to expand at a significant CAGR during the forecast period. Gastroparesis drugs include oral drugs such as ondansetron, Metoclopramide, and promethazine. These drugs help to reduce nausea and vomiting, which are common symptoms of gastroparesis. Oral medication is considered to be an effective treatment for gastroparesis.
Based on distribution channel, the idiopathic gastroparesis drugs market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is projected to hold a large market share. Availability of various products is anticipated to propel the distribution channel segment during the forecast period.
Idiopathic Gastroparesis Drugs Market Regional Outlook
The market is divided into five regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America is projected to account for a significant share of the idiopathic gastroparesis drugs market during the forecast period, owing to the rising number of FDA approvals for gastroparesis drugs and high awareness about these drugs for therapeutic purposes.
Europe is expected to hold a substantial market share during the forecast period, owing to increasing R&D activities for patients with complicated and untreated gastroparesis condition.
The market in Asia Pacific is anticipated to expand at a high CAGR during the forecast period, as underdeveloped countries are adopting the gastroparesis drugs treatment method for treating life-threatening gastric complications. Significant rise in the incidence of gastroenterology conditions is expected to boost the market
Key Benefits for Industry Participants & Stakeholders
- In-depth Analysis of the Global Idiopathic Gastroparesis Drugs Market
- Historical, Current, and Projected Market Size in terms of Value
- Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
- Industry Drivers, Restraints, and Opportunities Covered in the Study
- Recent Industry Trends and Developments
- Competitive Landscape & Strategies of Key Players
- Neutral Perspective on Global Idiopathic Gastroparesis Drugs Market Performance
Segments
By Drug
- Antiemetic drugs
- Prokinetic drugs
- Others
By Route of Administration
- Oral
- Intravenous
- Nasal
- Transdermal
By Distribution Channel
- Online Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Key Players
- EVOKE PHARMA
- Cadila Pharmaceuticals
- Janssen-Cilag Pty Limited
- Abbott
- ADVANZ PHARMA
- iNova Pharmaceuticals
- ANI Pharmaceuticals, Inc.
- AstraZeneca
- Intas Pharmaceuticals Ltd.
- Cipla Inc.
Competitive Landscape
- Key players in the idiopathic gastroparesis drugs market include EVOKE PHARMA, Cadila Pharmaceuticals, Janssen-Cilag Pty Limited, Abbott, ADVANZ PHARMA, iNova Pharmaceuticals, ANI Pharmaceuticals, Inc., AstraZeneca, Intas Pharmaceuticals Ltd., and Cipla Inc.
- Market players are pursuing key strategies such as acquisitions, collaborations, and geographic expansion, which is creating opportunities in the idiopathic gastroparesis drugs market.
Frequently Asked Questions
Additional company profiles are provided on request. For a discussion related to the above findings, click Speak to Analyst
Factors such as competitive strength and market positioning are key areas considered while selecting companies to be profiled.
Increasing prevalence of gastroparesis and rising approval of medications with different routes of administration are driving the idiopathic gastroparesis drugs market.
According to this Growth Market Reports report, the idiopathic gastroparesis drugs market is anticipated to register a CAGR of 4.1% during the forecast period, 2022-2030, with an anticipated valuation of USD 1,956.5 Million by the end of 2030.
Hospital pharmacies and retail pharmacies are the major distribution channels of idiopathic gastroparesis drugs.
Factors such as government regulations and R&D activities are expected to act as macroeconomic factors for the market.
Major manufacturers include AbbVie Inc., Janssen Biotech, Inc., Amgen Inc., AstraZeneca, Lilly, Merck & Co., Inc., Abbott, Novartis AG, Pfizer Inc., and Takeda Pharmaceutical Company Limited.
Demand for and supply of idiopathic gastroparesis drugs were slightly negatively affected during the pandemic, due to the scarcity of treatment processes.
In addition to market size (in US$ Million), the company market share (in % for the base year 2021), impact of key regulations, latest trends in treatment method, overview, product innovation in idiopathic gastroparesis drugs market, long-term market trends & opportunities, and scale of new market entrants are provided.
The base year considered for the global idiopathic gastroparesis drugs market report is 2021. The complete analysis period is 2015 to 2030, wherein, 2015 and 2020 are the historic years, and the forecast is provided from 2022 to 2030.
Table Of Content
Chapter 1 Executive SummaryChapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Idiopathic Gastroparesis Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Idiopathic Gastroparesis Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Idiopathic Gastroparesis Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Idiopathic Gastroparesis Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Idiopathic Gastroparesis Drugs Market Size & Forecast, 2015-2030
4.5.1 Idiopathic Gastroparesis Drugs Market Size and Y-o-Y Growth
4.5.2 Idiopathic Gastroparesis Drugs Market Absolute $ Opportunity
4.6 Regulations and Compliances: Gastroparesis Drugs Market
4.7 Comparative Analysis: Diabetic v/s Idiopathic v/s Surgical Gastroparesis
Chapter 5 Global Idiopathic Gastroparesis Drugs Market Analysis and Forecast By Drug Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities By Drug Type
5.1.2 Basis Point Share (BPS) Analysis By Drug Type
5.1.3 Absolute $ Opportunity Assessment By Drug Type
5.2 Idiopathic Gastroparesis Drugs Market Size Forecast By Drug Type
5.2.1 Antiemetic drugs
5.2.2 Prokinetic drugs
5.2.3 Others
5.3 Market Attractiveness Analysis By Drug Type
Chapter 6 Global Idiopathic Gastroparesis Drugs Market Analysis and Forecast By Route of Administration
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities By Route of Administration
6.1.2 Basis Point Share (BPS) Analysis By Route of Administration
6.1.3 Absolute $ Opportunity Assessment By Route of Administration
6.2 Idiopathic Gastroparesis Drugs Market Size Forecast By Route of Administration
6.2.1 Oral
6.2.2 Intravenous
6.2.3 Nasal
6.2.4 Transdermal
6.3 Market Attractiveness Analysis By Route of Administration
Chapter 7 Global Idiopathic Gastroparesis Drugs Market Analysis and Forecast By Distribution Channel
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities By Distribution Channel
7.1.2 Basis Point Share (BPS) Analysis By Distribution Channel
7.1.3 Absolute $ Opportunity Assessment By Distribution Channel
7.2 Idiopathic Gastroparesis Drugs Market Size Forecast By Distribution Channel
7.2.1 Online Pharmacies
7.2.2 Hospital Pharmacies
7.2.3 Retail Pharmacies
7.3 Market Attractiveness Analysis By Distribution Channel
Chapter 8 Global Idiopathic Gastroparesis Drugs Market Analysis and Forecast by Region
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Region
8.1.2 Basis Point Share (BPS) Analysis by Region
8.1.3 Absolute $ Opportunity Assessment by Region
8.2 Idiopathic Gastroparesis Drugs Market Size Forecast by Region
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa (MEA)
8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
9.1 Introduction
9.2 Current & Future Impact Analysis
9.3 Economic Impact Analysis
9.4 Government Policies
9.5 Investment Scenario
Chapter 10 North America Idiopathic Gastroparesis Drugs Analysis and Forecast
10.1 Introduction
10.2 North America Idiopathic Gastroparesis Drugs Market Size Forecast by Country
10.2.1 U.S.
10.2.2 Canada
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 North America Idiopathic Gastroparesis Drugs Market Size Forecast By Drug Type
10.6.1 Antiemetic drugs
10.6.2 Prokinetic drugs
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis By Drug Type
10.8 Absolute $ Opportunity Assessment By Drug Type
10.9 Market Attractiveness Analysis By Drug Type
10.10 North America Idiopathic Gastroparesis Drugs Market Size Forecast By Route of Administration
10.10.1 Oral
10.10.2 Intravenous
10.10.3 Nasal
10.10.4 Transdermal
10.11 Basis Point Share (BPS) Analysis By Route of Administration
10.12 Absolute $ Opportunity Assessment By Route of Administration
10.13 Market Attractiveness Analysis By Route of Administration
10.14 North America Idiopathic Gastroparesis Drugs Market Size Forecast By Distribution Channel
10.14.1 Online Pharmacies
10.14.2 Hospital Pharmacies
10.14.3 Retail Pharmacies
10.15 Basis Point Share (BPS) Analysis By Distribution Channel
10.16 Absolute $ Opportunity Assessment By Distribution Channel
10.17 Market Attractiveness Analysis By Distribution Channel
Chapter 11 Europe Idiopathic Gastroparesis Drugs Analysis and Forecast
11.1 Introduction
11.2 Europe Idiopathic Gastroparesis Drugs Market Size Forecast by Country
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 U.K.
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Europe Idiopathic Gastroparesis Drugs Market Size Forecast By Drug Type
11.6.1 Antiemetic drugs
11.6.2 Prokinetic drugs
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis By Drug Type
11.8 Absolute $ Opportunity Assessment By Drug Type
11.9 Market Attractiveness Analysis By Drug Type
11.10 Europe Idiopathic Gastroparesis Drugs Market Size Forecast By Route of Administration
11.10.1 Oral
11.10.2 Intravenous
11.10.3 Nasal
11.10.4 Transdermal
11.11 Basis Point Share (BPS) Analysis By Route of Administration
11.12 Absolute $ Opportunity Assessment By Route of Administration
11.13 Market Attractiveness Analysis By Route of Administration
11.14 Europe Idiopathic Gastroparesis Drugs Market Size Forecast By Distribution Channel
11.14.1 Online Pharmacies
11.14.2 Hospital Pharmacies
11.14.3 Retail Pharmacies
11.15 Basis Point Share (BPS) Analysis By Distribution Channel
11.16 Absolute $ Opportunity Assessment By Distribution Channel
11.17 Market Attractiveness Analysis By Distribution Channel
Chapter 12 Asia Pacific Idiopathic Gastroparesis Drugs Analysis and Forecast
12.1 Introduction
12.2 Asia Pacific Idiopathic Gastroparesis Drugs Market Size Forecast by Country
12.2.1 China
12.2.2 Japan
12.2.3 South Korea
12.2.4 India
12.2.5 Australia
12.2.6 South East Asia (SEA)
12.2.7 Rest of Asia Pacific (APAC)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Asia Pacific Idiopathic Gastroparesis Drugs Market Size Forecast By Drug Type
12.6.1 Antiemetic drugs
12.6.2 Prokinetic drugs
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis By Drug Type
12.8 Absolute $ Opportunity Assessment By Drug Type
12.9 Market Attractiveness Analysis By Drug Type
12.10 Asia Pacific Idiopathic Gastroparesis Drugs Market Size Forecast By Route of Administration
12.10.1 Oral
12.10.2 Intravenous
12.10.3 Nasal
12.10.4 Transdermal
12.11 Basis Point Share (BPS) Analysis By Route of Administration
12.12 Absolute $ Opportunity Assessment By Route of Administration
12.13 Market Attractiveness Analysis By Route of Administration
12.14 Asia Pacific Idiopathic Gastroparesis Drugs Market Size Forecast By Distribution Channel
12.14.1 Online Pharmacies
12.14.2 Hospital Pharmacies
12.14.3 Retail Pharmacies
12.15 Basis Point Share (BPS) Analysis By Distribution Channel
12.16 Absolute $ Opportunity Assessment By Distribution Channel
12.17 Market Attractiveness Analysis By Distribution Channel
Chapter 13 Latin America Idiopathic Gastroparesis Drugs Analysis and Forecast
13.1 Introduction
13.2 Latin America Idiopathic Gastroparesis Drugs Market Size Forecast by Country
13.2.1 Brazil
13.2.2 Mexico
13.2.3 Rest of Latin America (LATAM)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Latin America Idiopathic Gastroparesis Drugs Market Size Forecast By Drug Type
13.6.1 Antiemetic drugs
13.6.2 Prokinetic drugs
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis By Drug Type
13.8 Absolute $ Opportunity Assessment By Drug Type
13.9 Market Attractiveness Analysis By Drug Type
13.10 Latin America Idiopathic Gastroparesis Drugs Market Size Forecast By Route of Administration
13.10.1 Oral
13.10.2 Intravenous
13.10.3 Nasal
13.10.4 Transdermal
13.11 Basis Point Share (BPS) Analysis By Route of Administration
13.12 Absolute $ Opportunity Assessment By Route of Administration
13.13 Market Attractiveness Analysis By Route of Administration
13.14 Latin America Idiopathic Gastroparesis Drugs Market Size Forecast By Distribution Channel
13.14.1 Online Pharmacies
13.14.2 Hospital Pharmacies
13.14.3 Retail Pharmacies
13.15 Basis Point Share (BPS) Analysis By Distribution Channel
13.16 Absolute $ Opportunity Assessment By Distribution Channel
13.17 Market Attractiveness Analysis By Distribution Channel
Chapter 14 Middle East & Africa (MEA) Idiopathic Gastroparesis Drugs Analysis and Forecast
14.1 Introduction
14.2 Middle East & Africa (MEA) Idiopathic Gastroparesis Drugs Market Size Forecast by Country
14.2.1 Saudi Arabia
14.2.2 South Africa
14.2.3 UAE
14.2.4 Rest of Middle East & Africa (MEA)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Middle East & Africa (MEA) Idiopathic Gastroparesis Drugs Market Size Forecast By Drug Type
14.6.1 Antiemetic drugs
14.6.2 Prokinetic drugs
14.6.3 Others
14.7 Basis Point Share (BPS) Analysis By Drug Type
14.8 Absolute $ Opportunity Assessment By Drug Type
14.9 Market Attractiveness Analysis By Drug Type
14.10 Middle East & Africa (MEA) Idiopathic Gastroparesis Drugs Market Size Forecast By Route of Administration
14.10.1 Oral
14.10.2 Intravenous
14.10.3 Nasal
14.10.4 Transdermal
14.11 Basis Point Share (BPS) Analysis By Route of Administration
14.12 Absolute $ Opportunity Assessment By Route of Administration
14.13 Market Attractiveness Analysis By Route of Administration
14.14 Middle East & Africa (MEA) Idiopathic Gastroparesis Drugs Market Size Forecast By Distribution Channel
14.14.1 Online Pharmacies
14.14.2 Hospital Pharmacies
14.14.3 Retail Pharmacies
14.15 Basis Point Share (BPS) Analysis By Distribution Channel
14.16 Absolute $ Opportunity Assessment By Distribution Channel
14.17 Market Attractiveness Analysis By Distribution Channel
Chapter 15 Competition Landscape
15.1 Idiopathic Gastroparesis Drugs Market: Competitive Dashboard
15.2 Global Idiopathic Gastroparesis Drugs Market: Market Share Analysis, 2021
15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
15.3.1 EVOKE PHARMA
15.3.2 Cadila Pharmaceuticals
15.3.3 Janssen-Cilag Pty Limited
15.3.4 Abbott
15.3.5 ADVANZ PHARMA
15.3.6 iNova Pharmaceuticals
15.3.7 ANI Pharmaceuticals, Inc.
15.3.8 AstraZeneca
15.3.9 Intas Pharmaceuticals Ltd.
15.3.10 Cipla Inc.
Methodology
Related Reports
Some other reports from this category!
Our Clients
